All In Biotech

Drug Trial Radar · NCT01417091

Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta

A Randomized, Open Label Intra-patient Dose Escalation Study With an Untreated Reference Group to Evaluate Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Infusions of BPS804 in Adults With Moderate Osteogenesis Imperfecta

Last checked: Nov 19, 2026Latest source record: May 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Jun 2011

Primary completion

Dec 2012

Study completion Dec 2012

Sponsor

Lead sponsor
Ultragenyx Pharmaceutical IncIndustry
Sponsor type
Industry
First posted
Aug 16, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open label intra-patient dose escalation study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of BPS804 in adults with osteogenesis imperfecta (OI). Pharmacodynamic effect will be determined by serological biomarkers and radiologic assessments. In addition, tolerability and pharmacokinetics (PK) will be evaluated.

Conditions

  • Osteogenesis Imperfecta

Interventions

  • BPS804Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability (composite outcome: standard laboratory, (serious) adverse events)Time frame: Day 1 through 141
  2. Determination of pharmacodynamic effect by means of biomarkersTime frame: Day 1 and Day 43
  3. Change in Z-score from baseline to Day 141Time frame: Day 1 and Day 141

Locations

6 sites in 4 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Anaheim, California

  • Novartis Investigative Site

    Miramar, Florida

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Würzburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.